Invention Grant
- Patent Title: Selective HDAC1 and HDAC2 inhibitors
-
Application No.: US15214061Application Date: 2016-07-19
-
Publication No.: US09765066B2Publication Date: 2017-09-19
- Inventor: John H. van Duzer , Ralph Mazitschek
- Applicant: Acetylon Pharmaceuticals, Inc.
- Applicant Address: US MA Boston
- Assignee: REGENACY PHARMACEUTICALS, LLC
- Current Assignee: REGENACY PHARMACEUTICALS, LLC
- Current Assignee Address: US MA Boston
- Agency: Lathrop & Gage LLP
- Agent Brian C. Trinque
- Main IPC: C07D409/12
- IPC: C07D409/12 ; C07D401/12 ; C07D471/04 ; C07D231/56 ; C07D333/20 ; C07D215/48 ; C07D215/54 ; C07D209/08 ; C07D209/34 ; A61K31/4045 ; A61K31/4709 ; A61K31/496 ; A61K31/498 ; A61K31/5377
Abstract:
Provided herein are compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1 and/or HDAC2. Such diseases include cancer, sickle-cell anemia, beta-thalassemia, and HIV.
Public/Granted literature
- US20170044144A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS Public/Granted day:2017-02-16
Information query
